19:11 , Apr 25, 2019 |  BC Week In Review  |  Clinical News

Viela publishes Phase Ib data for CD40L antagonist in RA

Viela said the highest two doses of VIB4920 (formerly MEDI4920) significantly reduced disease activity in a Phase Ib trial to treat rheumatoid arthritis. Data were published in Science Translational Medicine . Viela first reported data...
21:34 , Apr 16, 2019 |  BC Extra  |  Clinical News

Wave down on Phase I safety data for DMD therapy

Following a setback last week for its Huntington disease program, Wave lost $9.55 (28%) to $24.47 on Tuesday after the company announced plans to test two lower doses of suvodirsen in a Phase II/III trial...
03:03 , Feb 15, 2019 |  BC Innovations  |  Tools & Techniques

Heartening predictors in diabetes

New biomarkers of cardiovascular risk could relieve a decade-old bottleneck for diabetes drug development, but validating them will require companies to invest in strategic trial designs, and public and private stakeholders to pool thinking. As...
02:00 , Nov 17, 2018 |  BioCentury  |  Emerging Company Profile

Sepset’s sepsis signature

Sepset Biosciences Inc.’s gene expression test detects an "endotoxin tolerance" signature that can diagnose sepsis as soon as patients appear in an emergency room, earlier than approved assays and thereby providing more time for antibiotics...
18:19 , Nov 9, 2018 |  BC Week In Review  |  Company News

Novartis teases prices of gene therapy, IL-1β mAb as game-changer

During its R&D day Nov. 5, Novartis AG (NYSE:NVS; SIX:NOVN) hinted at a multimillion dollar price tag for its gene therapy AVXS-101, and also discussed plans to disrupt the non-small cell lung cancer (NSCLC) landscape...
00:32 , Nov 6, 2018 |  BC Extra  |  Company News

Novartis teases price of gene therapy, IL-1β mAb as game-changer

During its R&D day Monday, Novartis AG (NYSE:NVS; SIX:NOVN) hinted at a multimillion dollar price tag for its gene therapy AVXS-101, and also discussed plans to disrupt the non-small cell lung cancer (NSCLC) landscape that...
19:54 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Esperion hypercholesterolemia candidate meets in fifth and final Phase III

Esperion Therapeutics Inc. (NASDAQ:ESPR) said bempedoic acid (ETC-1002) as monotherapy met the primary endpoint of reducing LDL-C in the Phase III CLEAR Wisdom (1002-047) trial to treat hypercholesterolemia in high-risk atherosclerotic cardiovascular disease (ASCVD) patients...
17:37 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
21:15 , Oct 22, 2018 |  BC Extra  |  Clinical News

GSK, MorphoSys RA therapy misses in Phase IIb

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said GSK3196165 (formerly MOR103) plus methotrexate missed the primary endpoint in the Phase IIb BAROQUE trial to treat moderate to severe rheumatoid arthritis in patients who had an inadequate response to...
20:32 , Oct 5, 2018 |  BC Week In Review  |  Clinical News

Arena's olorinab improves abdominal pain in Crohn's patients in Phase IIa

Arena Pharmaceuticals Inc. (NASDSAQ:ARNA) said olorinab (APD371) significantly improved average abdominal pain score from baseline to weeks four and eight in a Phase IIa trial to treat abdominal pain in patients with Crohn’s disease. The...